WallStSmart

Advanced Micro Devices Inc (AMD)vsBristol-Myers Squibb Company (BMY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Bristol-Myers Squibb Company generates 29% more annual revenue ($48.48B vs $37.45B). BMY leads profitability with a 15.0% profit margin vs 13.4%. AMD appears more attractively valued with a PEG of 1.05. AMD earns a higher WallStSmart Score of 61/100 (C+).

AMD

Buy

61

out of 100

Grade: C+

Growth: 9.3Profit: 6.0Value: 4.3Quality: 9.0
Piotroski: 6/9Altman Z: 3.74

BMY

Buy

60

out of 100

Grade: C+

Growth: 4.7Profit: 9.0Value: 6.7Quality: 4.5
Piotroski: 6/9Altman Z: 1.42
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AMD.

BMYUndervalued (+32.0%)

Margin of Safety

+32.0%

Fair Value

$88.08

Current Price

$56.16

$31.92 discount

UndervaluedFair: $88.08Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMD6 strengths · Avg: 9.7/10
Market CapQuality
$666.04B10/10

Mega-cap, among the largest globally

Revenue GrowthGrowth
37.8%10/10

Revenue surging 37.8% year-over-year

EPS GrowthGrowth
91.2%10/10

Earnings expanding 91.2% YoY

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.7410/10

Safe zone — low bankruptcy risk

Free Cash FlowQuality
$2.57B8/10

Generating 2.6B in free cash flow

BMY4 strengths · Avg: 9.3/10
Return on EquityProfitability
38.7%10/10

Every $100 of equity generates 39 in profit

Operating MarginProfitability
33.0%10/10

Strong operational efficiency at 33.0%

Market CapQuality
$114.68B9/10

Large-cap with strong market position

P/E RatioValuation
15.7x8/10

Attractively priced relative to earnings

Areas to Watch

AMD2 concerns · Avg: 3.0/10
Price/BookValuation
11.8x4/10

Trading at 11.8x book value

P/E RatioValuation
137.1x2/10

Premium valuation, high expectations priced in

BMY4 concerns · Avg: 2.3/10
Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

PEG RatioValuation
181.372/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.422/10

Distress zone — elevated risk

Debt/EquityHealth
2.551/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : AMD

The strongest argument for AMD centers on Market Cap, Revenue Growth, EPS Growth. Revenue growth of 37.8% demonstrates continued momentum. PEG of 1.05 suggests the stock is reasonably priced for its growth.

Bull Case : BMY

The strongest argument for BMY centers on Return on Equity, Operating Margin, Market Cap.

Bear Case : AMD

The primary concerns for AMD are Price/Book, P/E Ratio. A P/E of 137.1x leaves little room for execution misses.

Bear Case : BMY

The primary concerns for BMY are Revenue Growth, PEG Ratio, Altman Z-Score. Debt-to-equity of 2.55 is elevated, increasing financial risk.

Key Dynamics to Monitor

AMD profiles as a growth stock while BMY is a value play — different risk/reward profiles.

AMD carries more volatility with a beta of 2.40 — expect wider price swings.

AMD is growing revenue faster at 37.8% — sustainability is the question.

AMD generates stronger free cash flow (2.6B), providing more financial flexibility.

Bottom Line

AMD scores higher overall (61/100 vs 60/100) and 37.8% revenue growth. BMY offers better value entry with a 32.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Advanced Micro Devices Inc

TECHNOLOGY · SEMICONDUCTORS · USA

Advanced Micro Devices, Inc. (AMD) is an American multinational semiconductor company based in Santa Clara, California, that develops computer processors and related technologies for business and consumer markets. AMD's main products include microprocessors, motherboard chipsets, embedded processors and graphics processors for servers, workstations, personal computers and embedded system applications.

Visit Website →

Bristol-Myers Squibb Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.

Visit Website →

Want to dig deeper into these stocks?